Table 1.
Current development of RO4929097: active clinical trials
| Malignancy | Combination w/ | Phase | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Colorectal | Cetuximab | I/II | NCT01198535 |
| Brain Metastases | Whole-Brain Radiotherapy | I/II | NCT01217411 |
| Breast | Exemestane | I/II | NCT01149356 |
| Colorectal | 5-FU/LV/Oxaliplatin(FOLFOX), Bevacizumab | II | NCT01270438 |
| Breast (triple negative) | Paclitaxel, Carboplatin | I | NCT01238133 |
| Renal Cell Carcinoma | II | NCT01141569 | |
| Breast (hormone receptor positive) | Letrezole | Ib | NCT01208441 |
| Melanoma | Cisplatin, Vinblastin, Temozolomide | I/II | NCT01196416 |
| Sarcoma | GDC-0449 | I/II | NCT01154452 |
| Non-Small Cell Lung | Erolotinib | I | NCT01193881 |
| Melanoma (resectable) | II | NCT01216787 | |
| Glioma | I | NCT01269411 | |
| Multiple Myeloma | Autologous Stem-Cell Transplant | II | NCT01251172 |
| Glioblastoma Multiforme | II | NCT01122901 | |
| Endometrial and Renal Cell | I | NCT01198184 | |
| Non-Small Cell Lung | II | NCT01193868 |